Belvedere Trading
TPST icon

Belvedere Trading’s Tempest Therapeutics TPST Stock Holding History

Belvedere Trading’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,325
Closed -$54.7K – 1084
2025
Q3 		$54.7K Buy
+5,325
New +$46.2K ﹤0.01% 667

Other funds holding TPST

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Belvedere Trading's TPST Position: Q4 2025 in Review

Belvedere Trading sold out of Tempest Therapeutics (TPST) in Q4 2025, closing a stake of 5,325 shares — an estimated $54.7K sold.

Belvedere Trading first reported a position in TPST in Q3 2025 and held it in 1 quarter. The position peaked at $54.7K in Q3 2025. 21 funds tracked by Wall St. Rank hold TPST as of Q4 2025.

  • Belvedere Trading reported no remaining Tempest Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Belvedere Trading sold 5,325 Tempest Therapeutics shares in Q4 2025, an estimated $54.7K.
  • Belvedere Trading first reported a position in Tempest Therapeutics in Q3 2025 and held it in 1 quarter.
  • Belvedere Trading's Tempest Therapeutics position peaked at $54.7K in Q3 2025.
  • 21 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2025.

Based on Belvedere Trading's 13F filing for Q4 2025, filed 10 Feb 2026.